Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
HERZLIYA, Israel and CALGARY, Alberta, Nov. 24, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats" in the peer reviewed esteemed journal Frontiers in Pharmacology (https://doi.org/10.3389/fphar.2025.1689226) (1).
Two goats suffering from chronic and disabling painful condition were treated with subcutaneous Synthetic Liposomal Cannabidiol (LPT-CBD, 5 mg/kg) injections every six weeks for 10 months. Throughout the study, serial blood sampling was performed to assess CBD and its metabolite plasma concentrations and to evaluate hematological and biochemical profiles before and up to six weeks following each administration. Efficacy was assessed by the caregivers via quality of life (QoL) weekly scoring, and adverse effects were monitored. Key findings include:
- Repeated LPT-CBD injections (7 injections per goat) maintained sustained CBD plasma concentrations consistent with a slow-release pharmacokinetic profile.
- Favorable drug tolerability was observed throughout the study with no recorded adverse events.
- In contrast to repeated oral CBD consumption in humans, this study showed that repeated LPT-CBD injections did not elevate liver enzymes--markers typically associated with liver injury (2).
- Repeated administration of LPT-CBD resulted in sustained pain relief, improved mobility, and enhanced quality of life, consistently maintained during the study period (10 months).
The results of this study offer clinically translatable information. LPT-CBD injections every 6 weeks are practical, have shown no adverse effects, and provide long-term CBD plasma concentrations. Additionally, LPT-CBD demonstrated remarkable efficacy trends in pain control and wellbeing improvement for several weeks and can potentially provide similar results in people.
"The findings of this study highlight the sustained beneficial effects of LPT-CBD observed over 10 months of repeated administration said Professor Chezy Barenholz, Head of the Advisory Board. "LPT-CBD was designed for the treatment of chronic conditions through repeated monthly administrations, and this study provides promising translational evidence supporting this approach".
Dr. Eyal Kalo, Vice President of Research and Development added, "This study demonstrates that repeated LPT-CBD administration, designed as a non-opioid chronic pain therapy, does not elevate liver enzymes, supporting a favorable long-term safety profile. By comparison, repeated oral CBD intake has been linked to elevated liver enzymes and potential liver injury (2). These results strengthen the evidence supporting the long-term safety of LPT-CBD in humans".
Reference:
- Yael Shilo-Benjamini et al, Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats, Frontiers in Pharmacology 10 November 2025 https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1689226/full
- Jeffery Florian et al, Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults, A Randomized Clinical Trial, JAMA Internal Medicine September 2025 Volume185, Number 9 https://pubmed.ncbi.nlm.nih.gov/40622698/
About Innocan:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Image - https://mma.prnewswire.com/media/2831263/Graphic_abstract.jpg
Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg
SOURCE Innocan Pharma Corporation
Share this article